{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hung JT"],"funding":["Chang Gung Medical Foundation","Ministry of Science and Technology of Taiwan"],"pagination":["e004312"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9226869"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(6)"],"pubmed_abstract":["An international randomized phase II trial of Globo H (GH) vaccine, adagloxad simolenin/OBI-821 in 349 patients with metastatic breast cancer showed longer progression-free survival (PFS) in vaccinated patients who developed anti-Globo H (anti-GH) IgG than those who did not and the placebo group. The impacts of anti-GH IgM and GH expression on peak anti-GH IgG and clinical outcome were further evaluated. The titers of anti-GH IgG and IgM were determined by ELISA. GH expression in tumor was examined by immunohistochemical staining. Immunophenotyping was conducted by flow cytometry. Adagloxad simolenin elicited anti-GH IgM which peaked at titers ≥1:80 between weeks 5 and 13. The mean anti-GH IgG titer peaked at week 41 and decreased thereafter on the completion of vaccination. One log increa"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer."],"pmcid":["PMC9226869"],"funding_grant_id":["MOST109-2622-B-182A-002","OMRPG3C0047","OMRPG3C0048","CMRPG3M0441"],"pubmed_authors":["Hung JT","Huang CS","Lin YC","Ueng SH","Rugo HS","Yu AL","Chen MY","Chen IJ","Chen SC","Campbell MJ","Lin CY"],"additional_accession":[]},"is_claimable":false,"name":"The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer.","description":"An international randomized phase II trial of Globo H (GH) vaccine, adagloxad simolenin/OBI-821 in 349 patients with metastatic breast cancer showed longer progression-free survival (PFS) in vaccinated patients who developed anti-Globo H (anti-GH) IgG than those who did not and the placebo group. The impacts of anti-GH IgM and GH expression on peak anti-GH IgG and clinical outcome were further evaluated. The titers of anti-GH IgG and IgM were determined by ELISA. GH expression in tumor was examined by immunohistochemical staining. Immunophenotyping was conducted by flow cytometry. Adagloxad simolenin elicited anti-GH IgM which peaked at titers ≥1:80 between weeks 5 and 13. The mean anti-GH IgG titer peaked at week 41 and decreased thereafter on the completion of vaccination. One log increa","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-06-12T09:06:19.225Z","creation":"2025-02-19T04:37:55.917Z"},"accession":"S-EPMC9226869","cross_references":{"pubmed":["35732348"],"doi":["10.1136/jitc-2021-004312"]}}